FindTrial
Sign In

Advanced Glycation End Products in Uveitis and Immune-related Scleritis Patients

Advanced Glycation End Products in Uveitis and Immune-related Scleritis Patients

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200114004
Enrollment
60
Registered
2020-01-14
Start date
2019-10-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To measure AGEs level with non&#45

Interventions

Non&#45
invasive AGEs level measurement,Non&#45
invasive AGEs level measurement
Active Comparator Device,Sham Comparator Device
active,controlled

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Active immune-related uveitis Active immune-related scleritis

Exclusion criteria

Exclusion criteria: DM

Design outcomes

Primary

MeasureTime frame
advanced glaycation end products level in uveitis patients 2 advanced glycation end products level—

Secondary

MeasureTime frame
comparison of AGEs in uveitis versus controlled patients 2 advanced glycation end products level—

Countries

Thailand

Contacts

Public ContactSutasinee Boonsopon

Faculty of Medicine Siriraj Hospital, Mahidol University

sutasinee.boo@mahidol.edu0639034303

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026